LDS/Medical Tests/Human Immunodeficiency Virus 1 (HIV-1) RNA, Qualitative

Human Immunodeficiency Virus 1 (HIV-1) RNA, Qualitative

The Human Immunodeficiency virus type-1 (HIV-1) is a retrovirus that causes HIV disease and AIDS. Worldwide, there are over 33 million people infected. In the US, the Centers for Disease Control and Prevention (CDC) estimates that there are over a million HIV infected individuals, with one in five not knowing they are infected. Approximately 18,000 individuals die from HIV-related illnesses in the US each year.

The most common modes of HIV infection are through infected needles, sexual contact, and from mother to infant. Individuals were previously infected through blood and blood products; however, universal screening of the blood supply for the presence of this virus has stopped this mode of transmission. Once infected, the primary infection may be symptomatic, with patients developing flu-like symptoms; or asymptomatic, where patients do not realize they have been infected. After the primary infection, the body never is able to totally eliminate the virus and a long-term (chronic) infection ensues. Chronic infection results in depletion of the cells that fight infection, leaving the patient susceptible to a wide range of opportunistic organisms. It is infection with these organisms that ultimately prove detrimental to the patient.

There are two types of Human Immunodeficiency viruse, HIV-1 and HIV-2. HIV-1 is more common; HIV-2 is mainly in isolated areas of Africa. Both are similar in their mode of action. HIV infects and destroys a specific type of white blood cell (WBC), called a CD4 lymphocyte that is a major part of the body’s immune system. It is the subsequent depletion of these cells that results in the immune system becoming compromised, thus the term “immunocompromised.” Once the immune system is compromised, the body is susceptible to infections. Thus, the goal of HIV therapy is to keep the level of circulating virus low and the level of CD4 cells high.

The HIV-1 RNA, Qualitative assay is used for confirmation of infection after screening positive for HIV Infection. After confirmation of the infection, HIV-1 viral load is used to monitoring treatment and disease management.

  • Confirmation of HIV infection after screening positive
  • Troubleshooting inconsistent quantitative results during therapy monitoring

Positive in:

  • HIV-1 infection

Not Detected (Negative)

Real-time Polymerase Chain Reaction (PCR), Transcription Mediated Amplification (TMA), other molecular methods.

Plasma Citrate (Light Blue) or EDTA (Lavender). 

Spin and separate plasma and freeze.

Stability

  • Ambient: Unacceptable
  • Refrigerated: 4 days
  • Frozen: 60 days
HIV Viral Load, CD4/CD8 Ratio, CD4, HSV, CMV, HHV6.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Curr HIV/AIDS Rep. 2012 Jan 4. [PMID: 22215419]
  • New Microbiol. 2010 Jan;33(1):1-11. [PMID: 20402409]
  • JAMA. 2008 Aug 6;300(5):555-70. [PMID: 18677028]
  • Expert Rev Mol Diagn. 2007 May;7(3):237-46. [PMID: 17489731]
  • Curr Pharm Des. 2006;12(9):1045-63. [PMID: 16515485]
  • MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207. [PMID: 19357635]
  • Lennette EH, Smith TF (editors): Laboratory Diagnosis of Viral Infections, 3rd ed. Marcel Dekker (1999).
  • Murray PR et al (editors): Manual of Clinical Microbiology, 8th ed. ASM Press (2003).
  • Guidelines for the use of HIV-1 RNA levels in clinical practice have been published [(17); http://www.aidsinfo. nih.gov, http://www.iasusa.org].